Scientists Stop Pancreatic Cancer Before It Starts in Landmark Preclinical Study

University of Pennsylvania researchers tested KRAS-targeting drugs in mouse models of pancreatic cancer.

Treating microscopic precancerous lesions before tumors formed greatly delayed pancreatic ductal adenocarcinoma and extended survival.

The Science study provides preclinical evidence that pancreatic cancer may be intercepted at an early stage.

This could point to a new prevention-like strategy for a disease with very poor survival.